Cargando…
Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial
BACKGROUND: Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion (SPEBT) has been shown to be effective in treating SCD outs...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171865/ https://www.ncbi.nlm.nih.gov/pubmed/32312326 http://dx.doi.org/10.1186/s13063-020-4212-8 |
_version_ | 1783524153619382272 |
---|---|
author | Oakley, Laura L. Awogbade, Moji Brien, Sarah Briley, Annette Chorozoglou, Maria Drasar, Emma Johns, Jemma Rhodes, Elizabeth Robinson, Vicky Seed, Paul Sharif, Joseph Singh, Claire Telfer, Paul Thompson, Hilary Watt-Coote, Ingrid Howard, Jo Oteng-Ntim, Eugene |
author_facet | Oakley, Laura L. Awogbade, Moji Brien, Sarah Briley, Annette Chorozoglou, Maria Drasar, Emma Johns, Jemma Rhodes, Elizabeth Robinson, Vicky Seed, Paul Sharif, Joseph Singh, Claire Telfer, Paul Thompson, Hilary Watt-Coote, Ingrid Howard, Jo Oteng-Ntim, Eugene |
author_sort | Oakley, Laura L. |
collection | PubMed |
description | BACKGROUND: Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion (SPEBT) has been shown to be effective in treating SCD outside pregnancy, but evidence is lacking regarding its use during pregnancy. The aim of this study is to assess the feasibility and acceptability of conducting a future phase 3 randomised controlled trial (RCT) to establish the clinical and cost effectiveness of SPEBT in pregnant women with SCD. METHODS: The study is an individually randomised, two-arm, feasibility trial with embedded qualitative and health economic studies. Fifty women, 18 years of age and older, with SCD and a singleton pregnancy at ≤ 18 weeks’ gestation will be recruited from six hospitals in England. Randomisation will be conducted using a secure online database and minimised by centre, SCD genotype and maternal age. Women allocated to the intervention arm will receive SPEBT commencing at ≤ 18 weeks’ gestation, performed using automated erythrocytapheresis every 6–10 weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%. Women in the standard care arm will only receive transfusion when clinically indicated. The primary outcome will be the recruitment rate. Additional endpoints include reasons for refusal to participate, attrition rate, protocol adherence, and maternal and neonatal outcomes. Women will be monitored throughout pregnancy to assess maternal, sickle, and foetal complications. Detailed information about adverse events (including hospital admission) and birth outcomes will be extracted from medical records and via interview at 6 weeks postpartum. An embedded qualitative study will consist of interviews with (a) 15–25 trial participants to assess experiences and acceptability, (b) 5–15 women who decline to participate to identify barriers to recruitment and (c) 15–20 clinical staff to explore fidelity and acceptability. A health economic study will inform a future cost effectiveness and cost-utility analysis. DISCUSSION: This feasibility study aims to rigorously evaluate SPEBT as a treatment for SCD in pregnancy and its impact on maternal and infant outcomes. TRIAL REGISTRATION: NIH registry (www.clinicaltrials.gov), registration number NCT03975894 (registered 05/06/19); ISRCTN (www.isrctn.com), registration number ISRCTN52684446 (retrospectively registered 02/08/19). |
format | Online Article Text |
id | pubmed-7171865 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-71718652020-04-24 Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial Oakley, Laura L. Awogbade, Moji Brien, Sarah Briley, Annette Chorozoglou, Maria Drasar, Emma Johns, Jemma Rhodes, Elizabeth Robinson, Vicky Seed, Paul Sharif, Joseph Singh, Claire Telfer, Paul Thompson, Hilary Watt-Coote, Ingrid Howard, Jo Oteng-Ntim, Eugene Trials Study Protocol BACKGROUND: Pregnancies in women with sickle cell disease (SCD) are associated with a higher risk of sickle and pregnancy complications. Limited options exist for treating SCD during pregnancy. Serial prophylactic exchange blood transfusion (SPEBT) has been shown to be effective in treating SCD outside pregnancy, but evidence is lacking regarding its use during pregnancy. The aim of this study is to assess the feasibility and acceptability of conducting a future phase 3 randomised controlled trial (RCT) to establish the clinical and cost effectiveness of SPEBT in pregnant women with SCD. METHODS: The study is an individually randomised, two-arm, feasibility trial with embedded qualitative and health economic studies. Fifty women, 18 years of age and older, with SCD and a singleton pregnancy at ≤ 18 weeks’ gestation will be recruited from six hospitals in England. Randomisation will be conducted using a secure online database and minimised by centre, SCD genotype and maternal age. Women allocated to the intervention arm will receive SPEBT commencing at ≤ 18 weeks’ gestation, performed using automated erythrocytapheresis every 6–10 weeks until the end of pregnancy, aiming to maintain HbS% or combined HbS/HbC% below 30%. Women in the standard care arm will only receive transfusion when clinically indicated. The primary outcome will be the recruitment rate. Additional endpoints include reasons for refusal to participate, attrition rate, protocol adherence, and maternal and neonatal outcomes. Women will be monitored throughout pregnancy to assess maternal, sickle, and foetal complications. Detailed information about adverse events (including hospital admission) and birth outcomes will be extracted from medical records and via interview at 6 weeks postpartum. An embedded qualitative study will consist of interviews with (a) 15–25 trial participants to assess experiences and acceptability, (b) 5–15 women who decline to participate to identify barriers to recruitment and (c) 15–20 clinical staff to explore fidelity and acceptability. A health economic study will inform a future cost effectiveness and cost-utility analysis. DISCUSSION: This feasibility study aims to rigorously evaluate SPEBT as a treatment for SCD in pregnancy and its impact on maternal and infant outcomes. TRIAL REGISTRATION: NIH registry (www.clinicaltrials.gov), registration number NCT03975894 (registered 05/06/19); ISRCTN (www.isrctn.com), registration number ISRCTN52684446 (retrospectively registered 02/08/19). BioMed Central 2020-04-20 /pmc/articles/PMC7171865/ /pubmed/32312326 http://dx.doi.org/10.1186/s13063-020-4212-8 Text en © The Author(s). 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Study Protocol Oakley, Laura L. Awogbade, Moji Brien, Sarah Briley, Annette Chorozoglou, Maria Drasar, Emma Johns, Jemma Rhodes, Elizabeth Robinson, Vicky Seed, Paul Sharif, Joseph Singh, Claire Telfer, Paul Thompson, Hilary Watt-Coote, Ingrid Howard, Jo Oteng-Ntim, Eugene Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial |
title | Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial |
title_full | Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial |
title_fullStr | Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial |
title_full_unstemmed | Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial |
title_short | Serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (TAPS-2): study protocol for a randomised controlled feasibility trial |
title_sort | serial prophylactic exchange blood transfusion in pregnant women with sickle cell disease (taps-2): study protocol for a randomised controlled feasibility trial |
topic | Study Protocol |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7171865/ https://www.ncbi.nlm.nih.gov/pubmed/32312326 http://dx.doi.org/10.1186/s13063-020-4212-8 |
work_keys_str_mv | AT oakleylaural serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT awogbademoji serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT briensarah serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT brileyannette serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT chorozogloumaria serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT drasaremma serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT johnsjemma serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT rhodeselizabeth serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT robinsonvicky serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT seedpaul serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT sharifjoseph serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT singhclaire serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT telferpaul serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT thompsonhilary serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT wattcooteingrid serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT howardjo serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial AT otengntimeugene serialprophylacticexchangebloodtransfusioninpregnantwomenwithsicklecelldiseasetaps2studyprotocolforarandomisedcontrolledfeasibilitytrial |